Nicole E Spruijt1,2, Roy van den Berg1. 1. Da Vinci Clinic, Nieuwendijk 49, 5664HB Geldrop, the Netherlands. 2. Corresponding author: Dr Nicole E Spruijt, Da Vinci Clinic, Nieuwendijk 49, 5664HB Geldrop, the Netherlands, n.spruijt@davincikliniek.com.
Abstract
INTRODUCTION: Late radiation tissue injury (LRTI) after breast cancer may benefit from hyperbaric oxygen treatment (HBOT). This study aimed to report the LRTI symptom scores up to 12 months after HBOT and identify risk factors for poor scores. METHODS: A case-series of 67 patients who underwent a mean of 44 sessions of HBOT was analysed. LRTI symptoms were scored at four time points using the LENT-SOMA scale (Late Effects in Normal Tissues - Subjective, Objective, Management, and Analytic), a visual analog scale for pain, and the range of shoulder motion. RESULTS: Between starting HBOT and 12 months after HBOT 57 patients (85%) reported at least one point improvement in their LENT-SOMA score. Median pain and fibrosis scores improved significantly between the start and end of HBOT (P < 0.001), and remained stable three and 12 months after HBOT. The median breast oedema score improved significantly 12 months after HBOT (P = 0.003). Median shoulder abduction increased significantly from 90 to 165 degrees (P = 0.001) and median shoulder anteflexion increased significantly from 115 to 150 degrees (P = 0.004). Various risk factors were identified for poor scores despite HBOT; the most common risk factor was a poor score at start of HBOT. CONCLUSIONS: In this case-series, patients who underwent HBOT for LRTI after breast cancer reported significant improvement in pain, fibrosis, oedema, and shoulder movement. The improvement persisted up to 12 months after HBOT. A poor score at the start of HBOT was predictive for a poor score 12 months after HBOT. Copyright: This article is the copyright of the authors who grant Diving and Hyperbaric Medicine a non-exclusive licence to publish the article in electronic and other forms.
INTRODUCTION: Late radiation tissue injury (LRTI) after breast cancer may benefit from hyperbaric oxygen treatment (HBOT). This study aimed to report the LRTI symptom scores up to 12 months after HBOT and identify risk factors for poor scores. METHODS: A case-series of 67 patients who underwent a mean of 44 sessions of HBOT was analysed. LRTI symptoms were scored at four time points using the LENT-SOMA scale (Late Effects in Normal Tissues - Subjective, Objective, Management, and Analytic), a visual analog scale for pain, and the range of shoulder motion. RESULTS: Between starting HBOT and 12 months after HBOT 57 patients (85%) reported at least one point improvement in their LENT-SOMA score. Median pain and fibrosis scores improved significantly between the start and end of HBOT (P < 0.001), and remained stable three and 12 months after HBOT. The median breast oedema score improved significantly 12 months after HBOT (P = 0.003). Median shoulder abduction increased significantly from 90 to 165 degrees (P = 0.001) and median shoulder anteflexion increased significantly from 115 to 150 degrees (P = 0.004). Various risk factors were identified for poor scores despite HBOT; the most common risk factor was a poor score at start of HBOT. CONCLUSIONS: In this case-series, patients who underwent HBOT for LRTI after breast cancer reported significant improvement in pain, fibrosis, oedema, and shoulder movement. The improvement persisted up to 12 months after HBOT. A poor score at the start of HBOT was predictive for a poor score 12 months after HBOT. Copyright: This article is the copyright of the authors who grant Diving and Hyperbaric Medicine a non-exclusive licence to publish the article in electronic and other forms.
Authors: Joanne S Haviland; J Roger Owen; John A Dewar; Rajiv K Agrawal; Jane Barrett; Peter J Barrett-Lee; H Jane Dobbs; Penelope Hopwood; Pat A Lawton; Brian J Magee; Judith Mills; Sandra Simmons; Mark A Sydenham; Karen Venables; Judith M Bliss; John R Yarnold Journal: Lancet Oncol Date: 2013-09-19 Impact factor: 41.316
Authors: Susan Shanley; Kate McReynolds; Audrey Ardern-Jones; Roger Ahern; Indrajit Fernando; John Yarnold; Gareth Evans; Diana Eccles; Shirley Hodgson; Sue Ashley; Linda Ashcroft; Andrew Tutt; Elizabeth Bancroft; Susan Short; Gerald Gui; Lester Barr; Andrew Baildam; Anthony Howell; Gavin Royle; Lori Pierce; Douglas Easton; Rosalind Eeles Journal: Clin Cancer Res Date: 2006-12-01 Impact factor: 12.531
Authors: David N Teguh; René Bol Raap; Henk Struikmans; Cees Verhoef; Linetta B Koppert; Arne Koole; Yadi Huang; Rob A van Hulst Journal: Radiat Oncol Date: 2016-09-29 Impact factor: 3.481
Authors: Eva L Meier; Stefan Hummelink; Nina Lansdorp; Onno Boonstra; Dietmar Jo Ulrich Journal: Diving Hyperb Med Date: 2021-09-30 Impact factor: 1.228
Authors: Hillary Nepon; Tyler Safran; Edward M Reece; Amanda M Murphy; Joshua Vorstenbosch; Peter G Davison Journal: Semin Plast Surg Date: 2021-09-10 Impact factor: 2.195